Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women with or without children and good general health and in need of contraception.~* Regular menstrual cycle without hormonal contraceptives.~Exclusion Criteria:~* Pregnant or lactating.~* Last delivery or abortion less than 12 weeks ago.~* Previous pregnancies outside the womb.~* Previous pelvic infections.~* Abnormal bleeding.~* Abnormal uterine cavity.~* Climacteric signs.~* Genital cancer.~* Liver diseases.~* Alcoholism or drug abuse.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- LCS12 (Type: EXPERIMENTAL): Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro
- LCS16 (Type: EXPERIMENTAL): Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro
- IUS20 (Mirena) (Type: ACTIVE_COMPARATOR): Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro

Based on this trial design, predict the completion outcome and termination type (if applicable).